Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

211
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

304
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
304
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

133
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
133

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Evaluation of DDA- and DIA-Based Proteomic Workflows in Beryllium-Related Lung Disease.

bioRxiv : the preprint server for biology·2026
Same author

Molecular characterisation of progressive pulmonary sarcoidosis: protocol for a longitudinal multi-centre study to develop peripheral blood circulating biomarkers for predicting pulmonary sarcoidosis progression.

BMJ open·2026
Same author

Performance and generalizability impacts of incorporating location encoders into deep learning for dynamic PM<sub>2.5</sub> estimation.

GIScience & remote sensing·2026
Same author

High-Resolution Estimation of Daily PM<sub>2.5</sub> Levels in the Contiguous US Using Bi-LSTM with Attention.

Remote sensing·2026
Same author

Occupational Exposure to Ambient Air Pollution: At-Risk Worker Groups, Regulatory and Research Needs An Official American Thoracic Society Workshop Report.

Annals of the American Thoracic Society·2025
Same author

Consequences of Climate Change on the Emergence of Pathogenic, Environmentally Acquired Nontuberculous Mycobacteria.

Open forum infectious diseases·2025

Related Experiment Video

Updated: Jun 6, 2025

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica
05:03

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica

Published on: October 28, 2022

1.2K

Sarcoidosis in Beryllium Exposed Workers: A Case-Case Study.

Annyce S Mayer1,2, Margaret M Mroz1, Michael K Van Dyke1,2

  • 1Division of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, Colorado, USA.

American Journal of Industrial Medicine
|November 25, 2024
PubMed
Summary

Distinguishing beryllium-exposed sarcoidosis (Be-exp-Sarc) from chronic beryllium disease (CBD) is challenging. This study suggests Be-exp-Sarc may be distinct, with unique clinical features and genetic markers, potentially indicating a role for beryllium exposure.

Keywords:
beryllium lymphocyte proliferation testchronic beryllium diseasesarcoidosis

More Related Videos

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust
10:45

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust

Published on: January 6, 2023

2.1K
Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
05:18

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

247

Related Experiment Videos

Last Updated: Jun 6, 2025

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica
05:03

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica

Published on: October 28, 2022

1.2K
A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust
10:45

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust

Published on: January 6, 2023

2.1K
Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
05:18

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

247

Area of Science:

  • Pulmonary Medicine
  • Occupational Health
  • Immunology

Background:

  • Distinguishing beryllium-exposed sarcoidosis (Be-exp-Sarc) from chronic beryllium disease (CBD) is a diagnostic challenge.
  • The clinical distinction and potential etiologic role of beryllium in Be-exp-Sarc remain unclear.

Purpose of the Study:

  • To compare clinical characteristics and HLA DPB1 E69 genotypes of Be-exp-Sarc and CBD cases.
  • To identify distinguishing features between Be-exp-Sarc and CBD.

Main Methods:

  • A case-case study comparing 40 Be-exp-Sarc individuals with 40 frequency-matched CBD cases.
  • Analysis included demographics, exposure history, clinical, radiographic, and genetic data (HLA DPB1 E69).

Main Results:

  • Be-exp-Sarc cases were younger, had lower lung function, and more adenopathy and extra-thoracic manifestations than CBD.
  • HLA DPB1 E69 was significantly less frequent in Be-exp-Sarc (53%) compared to CBD (92%).
  • Lack of beryllium sensitization in Be-exp-Sarc and lack of extra-thoracic manifestations in CBD were absolute distinguishing features.

Conclusions:

  • Be-exp-Sarc may be a distinct entity from CBD.
  • Beryllium or other workplace exposures may play an etiologic role in Be-exp-Sarc.
  • Selection bias from heightened surveillance in beryllium workforces cannot be excluded as a factor.